Hypoplastic left heart syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2248OMIM:241550Q23.4
Who is this for?
Show terms as
5Active trials64Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect in which the structures on the left side of the heart are critically underdeveloped. This includes the left ventricle, mitral valve, aortic valve, and ascending aorta, which are too small or malformed to support normal systemic blood circulation. As a result, the right ventricle must pump blood to both the lungs and the rest of the body. HLHS is one of the most serious forms of congenital heart disease and is uniformly fatal without intervention. Affected newborns typically appear normal at birth but rapidly develop signs of cardiovascular collapse as the ductus arteriosus closes within the first days of life. Symptoms include cyanosis (bluish skin discoloration), rapid or labored breathing, poor feeding, lethargy, weak pulses, and cool extremities. HLHS accounts for approximately 2–3% of all congenital heart defects. The condition is slightly more common in males than females. Diagnosis is often made prenatally by fetal echocardiography or shortly after birth. Initial stabilization requires prostaglandin E1 infusion to maintain ductal patency. Definitive treatment involves a series of three staged open-heart surgical procedures: the Norwood procedure (performed in the neonatal period), the Glenn or hemi-Fontan procedure (at approximately 4–6 months), and the Fontan procedure (at 2–4 years of age). These surgeries reconfigure the circulation so that the right ventricle serves as the systemic ventricle. Cardiac transplantation is an alternative in some centers. Despite significant advances in surgical outcomes, HLHS remains associated with long-term complications including heart failure, arrhythmias, neurodevelopmental delays, and the need for lifelong cardiac follow-up. Survival has improved dramatically over recent decades, with many patients now reaching adulthood.

Also known as:

Clinical phenotype terms— hover any for plain English:

Mitral stenosisHP:0001718Maternal diabetesHP:0009800Hypoplastic aortic archHP:0012304Mitral atresiaHP:0011560
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

9 events
Jan 2026Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Mauro H. Schenone — NA

TrialENROLLING BY INVITATION
Sep 2025Seeking for Perfected Aortic Arch Reconstruction Using a Graphically Designed Patient-specific Surgical Patch

The Hospital for Sick Children — NA

TrialNOT YET RECRUITING
Aug 2025Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

Emory University — PHASE1

TrialNOT YET RECRUITING
Jun 2021Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Longeveron Inc. — PHASE2

TrialACTIVE NOT RECRUITING
Jun 2021Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD

Timothy J Nelson, MD, PhD — PHASE1

TrialACTIVE NOT RECRUITING
Feb 2021Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Carelon Research — PHASE3

TrialACTIVE NOT RECRUITING
Jun 2019Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

Timothy J Nelson, MD, PhD — PHASE2

TrialACTIVE NOT RECRUITING
Jun 2016Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)

Metcela Inc. — PHASE3

TrialRECRUITING
May 2016National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Children's Hospital Medical Center, Cincinnati

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Hypoplastic left heart syndrome.

5 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

5 recruitingView all trials with filters →
Phase 31 trial
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
Phase 3
Actively Recruiting
· Sites: Kanagawa; Okayama +2 more · Age: 06 yrs
Phase 22 trials
Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome
Phase 2
Active
PI: Frank Cetta, MD (Mayo Clinic) · Sites: Birmingham, Alabama; Los Angeles, California +6 more
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Phase 2
Active
PI: Stu Berger, MD (Ann & Robert H Lurie Children's Hospital of Chicag) · Sites: Los Angeles, California; Aurora, Colorado +8 more
N/A1 trial
Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome
N/A
Enrolling by Invitation
PI: Mauro Schenone, MD (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 045 yrs
Other1 trial
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Actively Recruiting
PI: Garick Hill, MD (Cininnati Children's Hospital Medical Center) · Sites: Birmingham, Alabama; Phoenix, Arizona +61 more

Specialists

Showing 25 of 64View all specialists →
GM
Ganga Krishnamurthy, MD
NEW YORK, NY
Specialist
PI on 1 active trial1 Hypoplastic left heart syndrome publication
GM
Garick Hill, MD
CINCINNATI, OH
Specialist
PI on 1 active trial1 Hypoplastic left heart syndrome publication
JM
Joseph W Rossano, M.D.
PHILADELPHIA, PA
Specialist
PI on 1 active trial
FM
Felice Su, MD
PALO ALTO, CA
Specialist
PI on 1 active trial
HM
Harold M Burkhart, M.D.
OKLAHOMA CITY, OK
Specialist
PI on 1 active trial
DM
David M Overman, M.D.
MINNEAPOLIS, MN
Specialist
PI on 1 active trial
KR
Kathleen A Mussatto, PhD, RN
Specialist
PI on 2 active trials
MM
Marianne Indrebø, MD
Specialist
PI on 1 active trial
JM
Jack Rychik, MD
PHILADELPHIA, PA
Specialist
PI on 1 active trial
FM
Frank Cetta, MD
CHICAGO, IL
Specialist
PI on 1 active trial
BM
Bryan H Goldstein, MD
Specialist
PI on 1 active trial
SM
Stu Berger, MD
REDWOOD CITY, CA
Specialist
PI on 1 active trial
MM
Mark A Fogel, MD
LONG BEACH, NY
Specialist
PI on 1 active trial
JM
James Tweddell, M.D.
Specialist
PI on 2 active trials
JM
James Jaggers, M.D.
LONGVIEW, TX
Specialist
PI on 2 active trials
RP
Ram Kumar Subramanyan, M.D., Ph.D.
LOS ANGELES, CA
Specialist
PI on 2 active trials
DM
David M. Overman, M.D.
MINNEAPOLIS, MN
Specialist
PI on 1 active trial
WM
Waldemar Carlo, M.D.
BIRMINGHAM, AL
Specialist
PI on 1 active trial
HM
Harold M. Burkhart, M.D.
OKLAHOMA CITY, OK
Specialist
PI on 1 active trial
BM
Benjamin Peeler, M.D.
NEW ORLEANS, LA
Specialist
PI on 1 active trial
JM
Joseph W. Rossano, M.D.
PHILADELPHIA, PA
Specialist
PI on 1 active trial
AM
Arpit Agarwal, MD
SAN ANTONIO, TX
Specialist
PI on 1 active trial1 Hypoplastic left heart syndrome publication
JM
John R Charpie, MD
ANN ARBOR, MI
Specialist
PI on 1 active trial
MM
Mark Fogel, MD
Philadelphia, Pennsylvania
Specialist

Rare Disease Specialist

PI on 3 active trials
WM
William Mahle, MD
MARIETTA, GA
Specialist
PI on 5 active trials1 Hypoplastic left heart syndrome publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hypoplastic left heart syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hypoplastic left heart syndromeForum →

No community posts yet. Be the first to share your experience with Hypoplastic left heart syndrome.

Start the conversation →

Latest news about Hypoplastic left heart syndrome

Disease timeline:

New recruiting trial: Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)

A new clinical trial is recruiting patients for Hypoplastic left heart syndrome

New recruiting trial: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

A new clinical trial is recruiting patients for Hypoplastic left heart syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hypoplastic left heart syndrome

What is Hypoplastic left heart syndrome?

Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect in which the structures on the left side of the heart are critically underdeveloped. This includes the left ventricle, mitral valve, aortic valve, and ascending aorta, which are too small or malformed to support normal systemic blood circulation. As a result, the right ventricle must pump blood to both the lungs and the rest of the body. HLHS is one of the most serious forms of congenital heart disease and is uniformly fatal without intervention. Affected newborns typically appear normal at birth but rapidly develop sig

How is Hypoplastic left heart syndrome inherited?

Hypoplastic left heart syndrome follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hypoplastic left heart syndrome typically begin?

Typical onset of Hypoplastic left heart syndrome is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Hypoplastic left heart syndrome?

Yes — 5 recruiting clinical trials are currently listed for Hypoplastic left heart syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hypoplastic left heart syndrome?

25 specialists and care centers treating Hypoplastic left heart syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.